TRPC1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1430047	0.56	3/20
Hydrochloric Acid (SCHEMBL5677898)	0.53	3/20
SCHEMBL2325526	0.69	2/20
SCHEMBL5539403	0.67	2/20
SCHEMBL1194642	0.67	2/20
SCHEMBL5533620	0.66	2/20
SCHEMBL1814204	0.65	2/20
SCHEMBL2722465	0.64	2/20
SCHEMBL1402810	0.62	2/20
SCHEMBL6070165	0.61	2/20
SCHEMBL7193923	0.60	2/20
SCHEMBL2731169	0.56	2/20
SCHEMBL2853811	0.56	2/20
SCHEMBL2860236	0.56	2/20
SCHEMBL1429965	0.54	2/20
SCHEMBL2941393	0.53	2/20
SCHEMBL1782567	0.53	2/20
SCHEMBL1402681	0.53	2/20
SCHEMBL6180211	0.53	2/20
SCHEMBL1335150	0.53	2/20

Clinical trials — most relevant to TRPC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Ginsenoside-Rd for Acute Ischemic Stroke	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases	PHASE1	COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8	EARLY_PHASE1	COMPLETED
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3	EARLY_PHASE1	COMPLETED
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.	nan	COMPLETED
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Dissecting the Heterogeneity of Oral Cancer Pain	nan	UNKNOWN
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin	nan	ENROLLING_BY_INVITATION
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	nan	UNKNOWN
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Visual Activity Evoked by Infrared in Humans After Dark Adaptation	nan	COMPLETED
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy	nan	ENROLLING_BY_INVITATION
A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin	nan	COMPLETED
The Natural History of TRPV4 Neuropathy	nan	RECRUITING
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis	nan	UNKNOWN
Trigeminal Endonasal Perception: A Predictor for Septoplasty Outcome	nan	COMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED
Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy	nan	UNKNOWN
Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children	nan	COMPLETED
Pulsed Radiofrequency in Chronic Lumbosacral Radicular Pain	nan	COMPLETED
TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients	nan	ACTIVE_NOT_RECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TRPC1 binder may also engage these)

Protein	Name	Similarity
Q61056	—	1.000	Q61056 →
Q9TUN9	—	1.000	Q9TUN9 →
O18784	—	1.000	O18784 →
Q9QX01	—	1.000	Q9QX01 →
Q9QX29	—	1.000	Q9QX29 →
O35119	—	1.000	O35119 →
TRPC4	Short transient receptor potential channel 4	0.999	landscape →
O62852	—	0.999	O62852 →
P48994	—	0.997	P48994 →
P19334	—	0.997	P19334 →
Q9QUQ5	—	0.995	Q9QUQ5 →
Q6R5A3	—	0.993	Q6R5A3 →
TRPC5	Short transient receptor potential channel 5	0.993	landscape →
Q9MYV9	—	0.993	Q9MYV9 →
Q9JIP0	—	0.993	Q9JIP0 →
P69744	—	0.993	P69744 →
P79100	—	0.993	P79100 →
Q9M8S6	—	0.992	Q9M8S6 →
Q6RX08	—	0.992	Q6RX08 →
Q9R186	—	0.991	Q9R186 →
Q2TV84	—	0.991	Q2TV84 →
Q63563	—	0.990	Q63563 →
P34586	—	0.990	P34586 →
ADCY2	Adenylate cyclase type 2	0.989	landscape →
Q704Y3	—	0.989	Q704Y3 →
Q9ULH0	—	0.989	Q9ULH0 →
Q2WEA5	—	0.989	Q2WEA5 →
E9PU17	—	0.989	E9PU17 →
B4LX81	—	0.989	B4LX81 →
Q697L1	—	0.988	Q697L1 →